What Santhera Pharmaceuticals does

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company headquartered in Pratteln, Switzerland, founded in 2004 and listed on the SIX Swiss Exchange (ticker: SANN). The company develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, with its primary commercial product being AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy (DMD). Vamorolone binds to the same glucocorticoid and mineralocorticoid receptors as traditional corticosteroids but modifies downstream gene transcription, providing comparable anti-inflammatory efficacy with substantially reduced side effects, including an 80% reduction in vertebral fractures, a 12.17 cm mean height advantage at 5 years, and lower cataract incidence relative to standard-of-care corticosteroids. Santhera also has Lonodelestat (POL6014) in clinical development for cystic fibrosis.

The company operates a hybrid commercialization model combining direct field sales in major European markets (Germany, Austria, Italy, Spain, UK, Switzerland) with exclusive licensing partnerships in other regions: Catalyst Pharmaceuticals for North America (up to USD 231 million plus royalties), Sperogenix Therapeutics for Greater China, and Nxera Pharma for Japan, South Korea, Australia, and New Zealand (up to USD 205 million plus royalties). Distribution agreements extend further reach into Russia, Central and Eastern Europe, Turkey, India, and GCC countries. Revenue is generated through direct product sales of AGAMREE to wholesalers and pharmacies in directly commercialized markets, combined with upfront payments, milestone receipts, and tiered royalties from licensing partners. The company also employs royalty monetization structures (with R-Bridge and Partners Group) to extend its operational runway toward its targeted Q3 2026 cash flow breakeven, supported by FY2025 revenue of CHF 77.4 million representing 98% year-over-year growth.

Name

Santhera Pharmaceuticals

Legal name

Santhera Pharmaceuticals (Schweiz) AG

Website

https://santhera.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company that develops and commercializes AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy, serving patients across the US, EU, UK, China, and APAC markets through direct sales and licensing partnerships.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals - Rare Neuromuscular Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Rare disease therapeutics
• Neuromuscular disease drugs
• Dissociative steroid therapy
• Duchenne muscular dystrophy treatment
• Specialty pharmaceuticals

Headquarters

HQ city

Liestal

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. AGAMREE Product Sales: Direct product sales of AGAMREE (vamorolone) for Duchenne muscular dystrophy in European markets where Santhera commercializes directly (Germany, Austria, Italy, Spain, UK), generating product revenue from pharmaceutical wholesalers and pharmacies.
2. North America Licensing Royalties: Out-licensed to Catalyst Pharmaceuticals for North America; Santhera receives royalties on net sales of AGAMREE in the US and Canada. Deal valued at up to USD 231 million plus royalties.
3. China Licensing Royalties: Out-licensed to Sperogenix Therapeutics for Greater China region; Santhera receives royalties on net sales of AGAMREE in China. Early access program launched in China in June 2024, with full approval from China's NMPA in December 2024.
4. Japan/APAC Licensing: Exclusive licensing agreement with Nxera Pharma for Japan, South Korea, Australia, and New Zealand. Deal includes USD 40 million upfront payment (USD 30M cash + USD 10M equity), plus potential milestone payments of up to USD 165 million and double-digit tiered royalties on net sales.
5. Royalty Monetization: Santhera monitized future royalty streams from Catalyst Pharmaceuticals (North America) and Sperogenix Therapeutics (China) for USD 13 million to support global AGAMREE launch.
6. Milestone Payments: Received milestone payments from regulatory approvals and commercial launches across various territories, contributing to non-recurring revenue.

Pricing tiers

Go-to-market motion1 record

Distribution channels7 records

Marketing channels6 records

Core offering

Santhera Pharmaceuticals develops, manufactures, and commercializes AGAMREE (vamorolone), a first-in-class dissociative steroid approved for the treatment of Duchenne muscular dystrophy (DMD). The company also has a pipeline asset, Lonodelestat (POL6014), under development for cystic fibrosis. Santhera commercializes AGAMREE directly in major European markets and through exclusive licensing partners in North America, China, and Japan/APAC.

Product overview

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on development and commercialization of innovative medicines for rare diseases. The company's primary commercial product is AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy (DMD) in the US, EU, UK, China, Hong Kong, Canada, and Switzerland. The product portfolio includes AGAMREE as the core commercial offering and Lonodelestat as a pipeline asset for cystic fibrosis. Santhera has out-licensed rights to vamorolone for North America to Catalyst Pharmaceuticals and for China to Sperogenix Therapeutics, while maintaining commercial rights in Europe and other regions. The company previously developed Raxone (idebenone) for Leber's Hereditary Optic Neuropathy and Puldysa for DMD but has divested these assets.

Differentiator

Problem solved

Functional benefit

Brands

• AGAMREE (vamorolone): First-in-class dissociative steroid treatment for Duchenne muscular dystrophy

Products and services

• AGAMREE (vamorolone) AGAMREE is a first-in-class dissociative steroid (vamorolone) approved for the treatment of Duchenne muscular dystrophy (DMD) in patients typically aged 4 years and older (expanding to 2+ years in EU following CHMP positive opinion). It binds to glucocorticoid and mineralocorticoid receptors but modifies downstream gene transcription, delivering anti-inflammatory efficacy comparable to standard corticosteroids with significantly reduced side effects (80% reduction in vertebral fractures, 12.17 cm height advantage at 5 years, fewer cataracts). It is for neuromuscular specialists, pediatricians, hospital pharmacies, and national health systems that reimburse orphan disease treatments.

Quantifiable outcome

• 80% reduction in vertebral fractures compared to standard corticosteroids (8.1% vs 41.9%)
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature1 record

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• PTC Therapeutics: US-based specialty pharmaceutical company developing and commercializing treatments for Duchenne muscular dystrophy and other rare disorders. Directly comparable as a DMD-focused rare-disease commercial-stage peer with overlapping physician call points and similar orphan-drug commercial dynamics.
• Sarepta Therapeutics: Leading commercial-stage DMD therapeutics company (Elevidys, EXONDYS 51, etc.). Competes for the same DMD patient population and neuromuscular specialists, with overlapping distribution and reimbursement infrastructure in the US and EU.
• Catalyst Pharmaceuticals: Santhera's exclusive North America licensee for AGAMREE and a US rare-disease commercial specialist (Firdapse, etc.). Closely linked commercially and a directly comparable rare-disease specialty pharma business model.
• Italfarmaco: Privately held Italian pharmaceutical company marketing deflazacort (the standard-of-care corticosteroid against which vamorolone competes) in DMD across multiple geographies. Direct therapeutic competitor in the same indication.

Emerging players

• ReveraGen BioPharma: Originating discoverer of vamorolone and licensor of the compound to Santhera. A clinical-stage rare-disease biotech whose commercial economics flow through Santhera but whose scientific footprint defines the platform.
• Mirum Pharmaceuticals: US rare-disease specialty pharma with growing international operations (where incoming Santhera CCO Marc Clausse previously worked). Comparable as a smaller, focused rare-disease commercial peer building global rare-disease infrastructure.

Broad incumbents

• Idorsia Pharmaceuticals: Swiss specialty pharmaceutical company and a significant Santhera shareholder (~17.7%). Comparable as a Switzerland-listed, late-stage commercial rare-disease and CNS-focused peer with similar operating profile and geographic base.
• Vifor Pharma: Swiss specialty pharma with established global rare-disease and nephrology commercial infrastructure. Many Santhera executives (Eklund, Kronenberg) came from Vifor, making it a relevant operational and strategic peer.
• BioMarin Pharmaceutical: Established global rare-disease specialty pharmaceutical company with a multi-asset commercial portfolio. Comparable as a larger, more diversified rare-disease commercial peer operating similar specialty distribution and reimbursement models.
• Recordati: European-headquartered specialty pharmaceutical group with a growing rare-disease franchise. Comparable as a European specialty pharma commercializing rare-disease treatments through similar national reimbursement pathways.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/santhera-pharmaceuticals-ltd
• Xx.com/santhera

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds14 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Santhera Pharmaceuticals